XenoPort, Inc. (NASDAQ: XNPT) announced today that it will provide
access via the World Wide Web to its presentation at the Cowen and
Company 35th Annual Health Care Conference. The live presentation will
occur at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) on Wednesday,
March 4, 2015. A replay of the presentation will also be available.
To access the live presentation via the Web, please go to www.XenoPort.com.
Please connect to the Web site at least 15 minutes prior to the live
presentation to ensure adequate time for any software downloads that may
be necessary to listen to the Webcast.
A replay of the Webcast can be accessed for a minimum of one month and
will be available approximately 24 hours after the live presentation.
About XenoPort
XenoPort, Inc. is a biopharmaceutical company focused on developing and
commercializing a portfolio of internally discovered product candidates
for the potential treatment of neurological disorders. XenoPort is
currently commercializing HORIZANT® (gabapentin enacarbil)
Extended-Release Tablets in the United States and developing its novel
fumaric acid ester product candidate, XP23829, as a potential treatment
for patients with moderate-to-severe chronic plaque-type psoriasis and
potentially for relapsing forms of multiple sclerosis. REGNITE®
(gabapentin enacarbil) Extended-Release Tablets is being marketed in
Japan by Astellas Pharma Inc. XenoPort granted exclusive world-wide
rights for the development and commercialization of its clinical-stage
oral product candidate, AP, to Indivior PLC for all indications.
XenoPort's pipeline of product candidates also includes a potential
treatment for patients with idiopathic Parkinson's disease.
To learn more about XenoPort, please visit the Web site at www.XenoPort.com.
HORIZANT, REGNITE and XENOPORT are registered trademarks of XenoPort,
Inc.
XNPT2G
Copyright Business Wire 2015